China Resources Sanjiu Pharmaceutical Co., Ltd. is a well-known brand of OTC and traditional Chinese medicine prescription drugs, OTC core products have influence in the cold/gastrointestinal/skin/orthopedic drug market, and is a listed company engaged in the research and development/production/sales of pharmaceutical products and related health services
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-controlled listed pharmaceutical company, formerly known as Shenzhen Nanfang Pharmaceutical Factory. On April 21, 1999, the company initiated the establishment of a joint-stock company. On March 9, 2000, it was listed on the Shenzhen Stock Exchange with the stock code 000999. The company officially joined China Resources Group in 2008. In February 2010, the company's name was officially changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd." CR Sanjiu is mainly engaged in the research and development, production, sales and related health services of pharmaceutical products, and is one of the "Top 100 Most Valuable Enterprises" listed on the main board of China.
After more than 20 years of unremitting efforts, especially at the end of 2007, since its merger into China Resources Group, China Resources Sanjiu has embarked on the track of rapid development, strengthening and developing its advantages in brand, products, and channel terminals. At present, the total market value of CR Sanjiu remains stable in the forefront of listed companies in the pharmaceutical industry.
At present, CR Sanjiu's main core business is positioned in OTC and traditional Chinese medicine prescription drugs, and OTC core products have a certain influence in the cold, gastrointestinal, skin and orthopedic drug markets. At the same time, it enjoys a high reputation in the traditional Chinese medicine injection industry, and has more than 10 varieties of traditional Chinese medicine injections, such as Shenfu Injection, Shenmai Injection, and Huabusu.
CR Sanjiu continues to focus on its main business, focusing its business on the two major fields of self-diagnosis and treatment and traditional Chinese medicine prescription drugs, actively building the "1 N" brand line, strengthening terminal coverage, and continuously improving product strength. Since 2008, it has successively divested non-core businesses such as real estate, food, and pharmaceutical retail; From 2008 to 2010, it successively acquired pharmaceutical companies in Huangshi, Nanchang, Huaibei and other places; In 2011, it integrated Hefei Shenlu, Benxi Sanyao, Shuanghe Hi-Tech and other enterprises under the Natural Medicine Division of Beijing Medicine. From 2012 to 2014, it successively acquired Guangdong Shunfeng, Guilin Tianhe, Linqing Qingwei, Jilin Hongjiu Heshantang, Hangzhou Laotongjun and other enterprises, enriched the product lines of skin medicine, orthopedic medicine, cold medicine, etc., expanded the planting and processing business of Chinese herbal medicines, and further enhanced the core competitiveness of the enterprise.
In December 2014, CR Sanjiu entered the "Blue Ocean" and launched the "Big Health and New Category" project. According to the changing trend of consumer behavior, the company strengthens the research and development of consumer demand, expands the big health market, enriches the business portfolio, and upgrades the business model; Relying on the existing category foundation and brand equity, it began to extend to health products, and completed the big health business planning and product preparation.
Starting from the height of industry development and the actual situation of the enterprise, CR Sanjiu has formulated a clear strategic plan, reviewed its strategic objectives from the three levels of scale, market position and core competitiveness, and is committed to becoming a "leader in the self-diagnosis and treatment market and an innovator in the Chinese medicine prescription drug market" in China, and its market share ranks among the forefront of China's pharmaceutical industry.
CR Sanjiu vigorously promotes organizational reform, starting from "one goal, one organization, one team, and one culture", breaking through the existing legal person framework and implementing the organizational structure of headquarters operation control. At present, CR Sanjiu has initially formed an operation and control structure to ensure the implementation of the strategy, integrating the original multiple legal entities into three business centers of production, marketing and R&D, and several functional management centers and departments such as finance, human resources and public affairs. At the same time, we will further deepen organizational reform, take customers as the guide, start from business processes, and build "four platforms" of marketing, production, R&D and functional management, so as to enhance customer value and promote the sustainable and stable growth of the company's business.
Sanjiu stomach TaiIt has been selling well in the market for more than 20 years, ranking second in the gastrointestinal drug market, and has been recognized by the majority of patients with stomach diseases, and has the reputation of "the king of gastric medicine".
Sanjiu Stomach Tai is an exclusive variety, and with its unique product advantages, it has been selected into the first batch of national essential drug lists; It is also recommended for the standard drug treatment plan of the Ministry of Health's "Clinical Pathway for Reflux Esophagitis County Hospitals" and the "Consensus Opinions on the Diagnosis and Treatment of Chronic Superficial Gastritis".
Details:
【Drug name】Sanjiu Gaotai Granules
【Properties】This product is brown to dark brown particles; Sweet and slightly bitter.
【Indications】Clearing away heat and dampness, promoting qi and blood, softening the liver and relieving pain. It is used for stomach pain caused by dampness and heat, qi stagnation and blood stasis, and the symptoms are vague pain in the abdomen, fullness and acid reflux, nausea and vomiting, and noisy intake and reduction; Superficial gastritis is seen in the above syndromes.
[Specification] 20 grams per bag.
【Approval number】National medicine quasi-word Z44020705
【Manufacturer】China Resources Sanjiu Pharmaceutical Co., Ltd
